Patents Assigned to HELMHOLTZ ZENTRUM MUNCHEN
-
Publication number: 20110306857Abstract: A method of multi-spectral opto-acoustic tomography (MSOT) imaging of a target tissue including a target tissue biomarker includes illuminating the target tissue with an illumination device emitting at least one pulsed illumination pattern at several illumination wavelengths, detecting pressure signals from the target tissue biomarker with a detector device, wherein the pressure signals being produced in the target tissue are in response to the illumination, and reconstructing a quantitative tomographic image of a distribution of the target tissue biomarker in the target tissue, wherein the pressure signals are analyzed using a photon propagation model which depends on an illuminating light fluence in the target tissue and on the illumination wavelengths, at least one spectral processing scheme, and an inversion scheme providing the tomographic image.Type: ApplicationFiled: July 25, 2008Publication date: December 15, 2011Applicant: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Daniel Razansky, Vasilis Ntziachristos
-
Publication number: 20110294721Abstract: The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; D is a peptide consisting of two hydrophobic amino acid residues; E is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; F is a peptide consisting of three amino acid residues selected from the group consisting of glycine and hydrophobic amino acid residues; G is an amino acid residue selected from the group consisting of hydrophobic and basic amino acid residues; H is a peptide consisting of two or three amino acid residues selected from the group consisting of serine and hydrophobic amino acid residues; I is a peptide consisting of two to four basic amino acid residues; or a pType: ApplicationFiled: September 24, 2009Publication date: December 1, 2011Applicant: Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GmbH)Inventors: Jörg Durner, Christian Lindermayr, Ruth Brack-Werner
-
Publication number: 20110294722Abstract: The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said residue(s) are hydrophobic amino acid residues; C is a basic amino acid residue or is absent; D is a peptide consisting of two hydrophobic amino acid residues or is absent; E is a peptide consisting of two basic amino acid residues; and F is a peptide consisting of two hydrophobic amino acid residues; or a peptidomimetic thereof; wherein the basic amino acid residue is selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residue is selected from the group consisting of leucine, alanine, valine, phenylalanine, isoleucine and methionine; and wherein said peptide or peptidomimetic has antimicrobial activity.Type: ApplicationFiled: September 24, 2009Publication date: December 1, 2011Applicant: HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWLET (GmbH)Inventors: Jörg Durner, Christian Lindermayr
-
Publication number: 20110236409Abstract: The present invention relates to set overlapping immunogenic peptides of a variable antigen, and uses thereof, in particular for diagnostic and therapeutic purposes. The present invention relates also to a sub-population of CD8 T cells associated with the non-progressive status in HIV-infected subjects.Type: ApplicationFiled: March 30, 2009Publication date: September 29, 2011Applicant: Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Mauro Severo Malnati, Paolo Lusso, Guido Poli, Antonio Cosma, Volker Erfle
-
Publication number: 20110224477Abstract: The disclosure relates to a therapeutic device for treatment of a patient, particularly for cancer treatment, which includes a radiation therapy apparatus for applying an ionizing radiation to the patient, and an integrated thermotherapeutic heating device for inducing a regional hyperthermia in the patient.Type: ApplicationFiled: October 8, 2008Publication date: September 15, 2011Applicant: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventor: Rolf Issels
-
Publication number: 20110222648Abstract: A scanner device for computed tomography imaging of an object, includes a measurement device including a source device arranged for irradiating the object with at least one beam and a detector device arranged for detecting radiation transmitted through the object, wherein the source device has a fixed position relative the detector device, and a carrier device accommodating the object in a position between the source device and the detector device, wherein the measurement device and the carrier device are capable of a scanning movement relative to each other, and the measurement device and the carrier device have a fixed spatial orientation during the scanning movement. Furthermore, a scanning method for computed tomography imaging of an object is described.Type: ApplicationFiled: June 5, 2009Publication date: September 15, 2011Applicant: Helmholtz Zentrum München Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)Inventors: Oleg Tischenko, Matthias Klaften, Christoph Hoeschen, Martin Hrabe de Angelis
-
Patent number: 8012470Abstract: According to the invention there is described a method for ex vivo immunization of humans and animals comprising the following steps of: a) isolating autologous tumor cells; b) treating the tumor cells to prevent the survival thereof following reinfusion; c) incubating the thus treated tumor cells with intact heterologous bispecific and/or trisepcific antibodies showing the following properties: ?—binding to a T cell; ?—binding to at least one antigen on a tumor cell; ?—binding, by their Fc portion (in the case of bispecific antibodies), or by a third specificity (in the case of trispecific antibodies) to Fc receptor-positive cells.Type: GrantFiled: July 20, 2005Date of Patent: September 6, 2011Assignee: Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)Inventors: Horst Lindhofer, Hans-Joachim Kolb, Reinhard Zeidler, Georg Bornkamm
-
Publication number: 20110059443Abstract: The present invention relates to a nucleic acid molecule encoding a polypeptide having a fluorescence emission activity with a maximum emission at 505 to 515 nm, wherein said nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2; (b) a nucleic acid molecule having the DNA sequence of SEQ ID NO: 1; (c) a nucleic acid molecule hybridizing under stringent conditions to the complementary strand of (i.Type: ApplicationFiled: August 1, 2008Publication date: March 10, 2011Applicant: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Jean-Marie Buerstedde, Hiroshi Arakawa
-
Publication number: 20110059133Abstract: The present invention discloses an ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens for use in the prophylaxis and treatment of patients with a reduced T cell activity in order to prevent or treat growth of EBV infected B cells.Type: ApplicationFiled: November 27, 2008Publication date: March 10, 2011Applicant: Helmholtz Zentrum Munchen Deutsches Krebsfor schungszentrum Fur Gesundheit Und Unwelt (GMBH)Inventors: Dinesh Adhikary, Uta Behrends, Josef Mautner, Henri-Jacques Delecluse, Regina Feederle
-
Publication number: 20110061118Abstract: The present invention relates to a DNA molecule comprising: (a) a first DNA sequence comprising: (aa) a coding sequence giving rise upon transcription to a factor that contributes to the reprogramming of a somatic cell into an induced pluripotent stem (iPS) cell; (ab) a promoter mediating the transcription of said coding sequence; and (ac) two sequence motifs that mediate excision of (aa) and/or (ab) from the DNA molecule, wherein one sequence motif is positioned 5? and the other sequence motif is positioned 3? of the sequence to be excised; (b) a second DNA sequence comprising a sequence motif that mediates site-specific integration of (a) into another DNA molecule.Type: ApplicationFiled: March 17, 2009Publication date: March 10, 2011Applicant: Helmholtz Zentrum MunchenInventors: Ralf Kühn, Wolfgang Wurst
-
Publication number: 20100299771Abstract: The present invention relates to a combination of DNA segments comprising: (a) a first segment comprising in 5? to 3? or 3? to 5? order: (aa) a promoter; (ab) a first DNA sequence comprising: (i) a DNA sequence giving rise upon transcription to the sense strand of an shRNA molecule; (ii) a transcriptional stop element which is flanked by a first type of recombinase recognition sequences; and (iii) a DNA sequence giving rise upon transcription to the antisense strand of an shRNA molecule; (b) a second segment comprising in 5? to 3? or 3? to 5? order: (ba) a promoter; (bb) a second DNA sequence comprising: (i) a DNA sequence giving rise upon transcription to the sense strand of an shRNA molecule; (ii) a transcriptional stop element which is flanked by a second type of recombinase recognition sequences; and (iii) a DNA sequence giving rise upon transcription to the antisense strand of an shRNA molecule; wherein (i) said first type of recombinase recognition sequences are recognized and recombined by a recombinasType: ApplicationFiled: September 17, 2008Publication date: November 25, 2010Applicant: HELMHOLTZ ZENTRUM MUNCHEN- DEUTSCHES FORSCHUNGZENTRUM FUR GESUNDHEIT UND UMWELT(GMBH)Inventors: Ralf Kühn, Wolfgang Wurst, Patricia Steuber-Buchberger
-
Publication number: 20100284976Abstract: The invention relates to a method for in vitro maturation of at least one immature dendritic cell, comprising stimulating said immature dendritic cell with TNF?, IL-1?, IFN?, a TLR7/8 agonist and prostaglandin E2 (PG). Furthermore, the invention relates to a composition comprising said factors as well as to mature dendritic cells produced by the method of the invention.Type: ApplicationFiled: March 28, 2007Publication date: November 11, 2010Applicant: HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Dolores J. Schendel, Anke Zobywalski, Iris Bigalke
-
Patent number: 7803617Abstract: The present invention is directed to a conditional gene vector system and to a host cell, which has been transfected with such a vector system. The present invention is further directed to a combined preparation comprising the vector system of the invention and an interfering agent. Furthermore, a pharmaceutical composition and its use in the treatment of hemophilia, diabetes, rheumatoid arthritis, genetic immunodeficiency, and graft versus host disease is provided.Type: GrantFiled: February 13, 2007Date of Patent: September 28, 2010Assignee: Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)Inventors: Wolfgang Hammerschmidt, Sibille Humme, Dagmar Pich, Aloys Schepers
-
Publication number: 20100242127Abstract: The present invention relates to a method for identifying a compound capable of modulating an anxiety or depression disorder comprising the steps of: (a) contacting a composition comprising a B-Raf protein or a B-Raf gene in expressible form or a transcript thereof with a compound under conditions that allow for an interaction of the B-Raf protein or the B-Raf gene or a transcript thereof and the compound; and (b) measuring whether said interaction, if any, results in (i) a change of B-Raf kinase activity compared to B-Raf kinase activity in the absence of said compound; (ii) a modulation of the expression of the B-Raf gene compared to B-Raf gene expression in the absence of said compound; or (iii) the formation of a complex between the compound and the B-Raf protein, wherein such a change in activity, modulation of expression or the formation of a complex is indicative of the compound being a modulator of an anxiety or depression disorder.Type: ApplicationFiled: June 3, 2008Publication date: September 23, 2010Applicant: HELMHOLTZ ZENTRUM MUNCHENInventors: Christiane Hitz, Sabine Hölter, Ralf Kühn, Wolfgang Wurst, Benedikt Wefers
-
Patent number: 7731950Abstract: This invention is directed to therapeutic compositions containing non-MHC-restricted T-cells/NK-cells in combination with MHC-restricted T-cells and especially to therapeutic compositions, which comprise LAK cells. Furthermore, the present invention is directed to the use of the above combination in the treatment of tumors in humans, which tumors show a missing, low or aberrant expression of MHC class 1a or 1b molecules. By using the aforementioned compositions/combinations it is possible to provide a balanced selective pressure against emergence of tumor cell variants that would otherwise escape immune detection.Type: GrantFiled: July 5, 2002Date of Patent: June 8, 2010Assignee: Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)Inventors: Elfriede Noessner, Elisabeth Weiss, Dolores Schendel, Christine Falk
-
Publication number: 20090310738Abstract: Imaging apparatus, for analyzing an object, comprising: a radiation source for transmission of radiation through said object in a section plane of said object; a radiation detector for detecting said radiation in said section plane of said object after transmission through said object; and a masking device for masking out a part of said radiation, wherein said masked part of said radiation is movable in said section plane relative to said radiation detector during said analysis of said object.Type: ApplicationFiled: July 4, 2007Publication date: December 17, 2009Applicant: Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt(GmbH)Inventors: Oleg Tischenko, Christoph Hoeschen
-
Patent number: 7573975Abstract: An irradiation method, in particular for imaging a region of investigation (2) of an object (1), comprises generating at least one energy input beam (3) with at least one energy input beam source (210), wherein the at least one energy input beam (3) comprises a plurality of individual energy input beam components (3.1, 3.2, 3.3, . . . ), and irradiating the region of investigation (2) with the at least one energy input beam (3) along a plurality of projection directions, wherein the energy input beam components (3.1, 3.2, 3.3, . . . ) are formed with at least one beam mask (211) made of an energy input shielding material with through holes. Furthermore, imaging methods and devices for irradiating or imaging the object are described.Type: GrantFiled: December 21, 2005Date of Patent: August 11, 2009Assignees: State of Oregon Acting By and Through the State Board of Higher Education on Behalf of the University of Oregon, Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit (GmbH)Inventors: Yuan Xu, Oleg Tischenko, Christoph Hoeschen
-
Patent number: 7498144Abstract: A method for the identification and/or quantification of GBP-1 or fragments of this protein in the culture supernatant of a tissue sample, a body fluid sample or a sample from a cell culture supernatant is described.Type: GrantFiled: December 19, 2003Date of Patent: March 3, 2009Assignee: Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)Inventors: Michael Stürzl, Clara Lubeseder-Martellato, Eric Guenzi, Elisabeth Kremmer